The Gilead Sciences Inc. (GILD) Rating Increased to Outperform at BMO Capital Markets

The Gilead Sciences Inc. (GILD) Rating Increased to Outperform at BMO Capital Markets

Gilead Sciences Inc. (NASDAQ:GILD) was upgraded by equities research analysts at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday. The firm presently has a $84.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $98.00. BMO Capital Markets’ price target suggests a potential upside of 11.35% from the stock’s current price.

A number of other equities analysts also recently weighed in on the company. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research note on Wednesday, October 26th. Jefferies Group upped their price objective on Gilead Sciences from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, October 25th. Cowen and Company set a $120.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Sunday, October 23rd. Piper Jaffray Cos. reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Saturday, October 22nd. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $100.00 price objective (down previously from $122.00) on shares of Gilead Sciences in a research note on Tuesday, October 18th. Ten investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $97.90.

Shares of Gilead Sciences (NASDAQ:GILD) traded up 0.19% during midday trading on Wednesday, hitting $75.44. The company’s stock had a trading volume of 3,068,606 shares. Gilead Sciences has a 52-week low of $71.39 and a 52-week high of $108.63. The firm has a market cap of $99.39 billion, a P/E ratio of 6.98 and a beta of 1.25. The stock’s 50 day moving average is $74.56 and its 200-day moving average is $80.20.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing analysts’ consensus estimates of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business earned $7.40 billion during the quarter, compared to analysts’ expectations of $7.47 billion. During the same quarter in the previous year, the firm earned $3.22 EPS. Gilead Sciences’s quarterly revenue was down 9.6% on a year-over-year basis. Equities analysts predict that Gilead Sciences will post $11.47 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.49%. The ex-dividend date is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio is 17.44%.

In related news, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the completion of the sale, the insider now owns 3,287,810 shares of the company’s stock, valued at $254,739,518.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the sale, the director now directly owns 121,761 shares of the company’s stock, valued at approximately $9,115,028.46. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. CWM LLC boosted its stake in shares of Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 17 shares in the last quarter. Tarbox Group Inc. boosted its stake in shares of Gilead Sciences by 0.4% in the third quarter. Tarbox Group Inc. now owns 6,522 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 27 shares in the last quarter. Cadence Bank NA boosted its stake in shares of Gilead Sciences by 0.8% in the second quarter. Cadence Bank NA now owns 3,727 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 28 shares in the last quarter. Marble Harbor Investment Counsel LLC boosted its stake in shares of Gilead Sciences by 0.9% in the second quarter. Marble Harbor Investment Counsel LLC now owns 3,330 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 30 shares in the last quarter. Finally, Birch Hill Investment Advisors LLC boosted its stake in shares of Gilead Sciences by 0.9% in the second quarter. Birch Hill Investment Advisors LLC now owns 3,336 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 30 shares in the last quarter. 76.65% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Related posts

Leave a Comment